ARS Pharmaceuticals, Inc. (SPRY)
D
Pipeline Grade
Financial Position (from SEC Filings)
$24.3M
Cash & Equivalents
$45.0M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$788M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06834165 | Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After O... | PHASE4 | Recruiting | 600 |
| NCT06927999 | An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria | PHASE2 | Recruiting | 42 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.